How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Diabetes Needle Market
- By Needle Type: Pen Needles, Syringe Needles, Insulin Pump Needles, Safety Needles
- By Needle Length: 4 mm, 5 mm, 6 mm, 8 mm, 12.7 mm
- By Needle Gauge: 31G, 32G, 33G, 34G
- By End User: Hospitals, Clinics, Home Care Settings, Specialty Diabetes Centers
- By Material: Stainless Steel, Silicone Coated Needles
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Pen Needles leads By Needle Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Diabetes Needle Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Needle Type 4
Needle Length 5
Needle Gauge 4
End User 4
Material 2
Companies profiled
Becton Dickinson and Company (BD)
Terumo Corporation
Owen Mumford Ltd.
Nipro Corporation
Ypsomed AG
Smiths Medical
B. Braun Melsungen AG
HMD Needle
Jiangsu Yuyue Medical Equipment & Supply Co. Ltd.
Shandong Weigao Group Medical Polymer Company Limited
Ningbo David Medical Device Co. Ltd.
Shanghai MicroPort Medical (Group) Co. Ltd.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Becton Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Owen Mumford Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Nipro Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Ypsomed AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Smiths Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →B. Braun Melsungen AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →HMD Needle
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Jiangsu Yuyue Medical Equipment & Supply Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Shandong Weigao Group Medical Polymer Company Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Ningbo David Medical Device Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Shanghai MicroPort Medical (Group) Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Bionime Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sahajanand Medical Technologies Pvt. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Unilife Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,472M by 2033 · 7.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Pen Needles46.4
- Syringe Needles15.9
- Insulin Pump Needles14.4
- Safety Needles23.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,042M → $2,003M · 8.5%
Europe$726.2M → $1,271M · 7.2%
Asia Pacific$663.0M → $1,064M · 6.1%
Latin America$410.5M → $724.7M · 7.4%
Middle East and Africa$315.7M → $543.1M · 7.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.072026
7.082027
7.092028
7.092029
7.112030
7.122031
7.152032
7.162033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Becton Dickinson and Company (BD)22.5
- Terumo Corporation17.7
- Owen Mumford Ltd.9.3
- Nipro Corporation8.4
- Ypsomed AG8.1
- Smiths Medical6.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Needle Type17.0%
Needle Length31.4%
Needle Gauge25.5%
End User12.3%
Material13.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.7
- Europe22.7
- Asia Pacific19.0
- Latin America12.9
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Becton Dickinson and Company (BD) | 82 | 78 | 99 | 95 | 74 | 95 | 87 |
| Terumo Corporation | 81 | 78 | 74 | 75 | 85 | 82 | 79 |
| Owen Mumford Ltd. | 65 | 63 | 86 | 82 | 65 | 66 | 71 |
| Nipro Corporation | 65 | 73 | 69 | 66 | 64 | 73 | 68 |
| Ypsomed AG | 56 | 60 | 57 | 55 | 74 | 70 | 62 |
| Smiths Medical | 67 | 64 | 69 | 62 | 53 | 50 | 61 |
| B. Braun Melsungen AG | 47 | 43 | 56 | 59 | 51 | 43 | 50 |
| HMD Needle | 38 | 35 | 38 | 39 | 35 | 51 | 39 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Becton Dickinson and Company (BD)
- Terumo Corporation
- Owen Mumford Ltd.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Becton Dickinson and Company (BD) | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Terumo Corporation | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Owen Mumford Ltd. | ✓ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Nipro Corporation | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Ypsomed AG | ◐ | ◐ | − | − | ✓ | ✓ |
| Smiths Medical | − | − | ✓ | ◐ | ◐ | − |
| B. Braun Melsungen AG | − | − | ◐ | ◐ | − | − |
| HMD Needle | ◐ | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Becton Dickinson and Company (BD)87
2Terumo Corporation79
3Owen Mumford Ltd.71
4Nipro Corporation68
5Ypsomed AG62
6Smiths Medical61
7B. Braun Melsungen AG50
8HMD Needle39
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Becton Dickinson and Company (BD)Terumo Corporation
Challenger2
Strong scale, closing on the leaders.
Owen Mumford Ltd.Nipro Corporation
Contender2
Focused players with pockets of strength.
Ypsomed AGSmiths Medical
Niche2
Specialists in a single segment or region.
B. Braun Melsungen AGHMD Needle
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Needle Type in North America, then scale across Diabetes Needle Market — a $292M beachhead inside a $4.52B market.
Beachhead (SOM)$292Mobtainable near-term
Serviceable (SAM)$1.83Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Pen Needles
Best fit — highest urgency & budget in Needle Type.
Economic buyer80 fit
Syringe Needles
Strong fit — clear ROI and a fast path to value.
End user65 fit
Insulin Pump Needles
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Needle Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Needle Length & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Needle Gauge
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel28%
Digital / self-serve20%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Needle Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Diabetes Needle Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified21%
Evaluation14%
Closed-won6%
$8.4KCAC
$47KLTV
5.6:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Diabetes Needle Market is a high-growth opportunity — $12.7B by 2033, compounding at 11.3%.
TAM · 2025$5.42Btoday
TAM · 2033$12.7Bforecast
CAGR11.3%2027–2033
Cumulative$77.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$12.7BTotal addressable market
SAM$4.63BServiceable available market
SOM$991MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.3% CAGR
Demand compounds through 2033, outpacing GDP across Needle Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Needle Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$12.7BLarge & growingTAM by 2033 at 11.3% CAGR
$4.63BServiceable nowreachable with today’s model
$991MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$9.91BBear7.3% CAGR
$12.7BBase11.3% CAGR
$16.3BBull14.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Needle Length optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Diabetes Needle Market — a $3.94B market by 2033. Plan: grow share from 7.3% to 11.3%.
Market size · 2033$3.94Btotal addressable
Market CAGR5.6%2027–2033
Target share11.3%from 7.3% today
Revenue ambition$445Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.3% | 11.3% | Ahead |
| Revenue | $268M | $445M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 29.7% | 39.2% | At risk |
| Customer retention | 84.2% | 93.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Needle Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Needle Length capability
A defensible second engine — invest in Needle Length to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Needle Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Needle Length
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $46M capacity & capability investment
- Greenlight bolt-on M&A in Needle Length
- Authorise North America expansion plan
- Fund R&D program for Needle Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Diabetes Needle Market conversation — a $9.74B market you can size, segment and defend in minutes.
Market size · 2033$9.74Btotal opportunity
Growth9.6%CAGR to 2033
Addressable buyers1,376+accounts in scope
Typical ROI6.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Needle Type
Goal Grow share in Needle Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.3×return on cost, year one
< 3 mopayback period
$79K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Becton Dickinson and Company (BD)Terumo CorporationOwen Mumford Ltd.Nipro CorporationYpsomed AGSmiths MedicalB. Braun Melsungen AGHMD Needle+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Diabetes Needle Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Diabetes Needle Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Diabetes Socks Market
Market size, share, segmentation and regional forecast.
$384M market · 2025 base year
View reportDiabetes Test Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportDiabetes World Drug Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportDiabetic Care Devices Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportDiabetic Care Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportDiabetic Drugs Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportDiabetic Eye Disease Device Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportDiabetic Eye Surgery Device Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportDiabetic Foot Care Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportDiabetic Foot Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportDiabetic Foot Ulcer (DFU) Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportDiabetic foot ulcers (DFUs) Treatment Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.